Fig. 3.

PET/CT and liquid biopsy monitoring the efficacy of haplo-CAR T cell therapy. a Whole body PET/CT image before CART therapy and 45 days after haplo-CAR T cell therapy. b Lung slice of tumor infiltration before CAR T cell therapy and 45 days after haplo-CAR T cell therapy. c The mutant percent of TP53 gene p.Thr253Profs*92 in circulating tumor DNA by liquid biopsy before CAR T cell therapy, in 1 and 2 months after haplo-CAR T cell therapy